ES2808728T3 - Agente terapéutico para cáncer sólido - Google Patents

Agente terapéutico para cáncer sólido Download PDF

Info

Publication number
ES2808728T3
ES2808728T3 ES15751324T ES15751324T ES2808728T3 ES 2808728 T3 ES2808728 T3 ES 2808728T3 ES 15751324 T ES15751324 T ES 15751324T ES 15751324 T ES15751324 T ES 15751324T ES 2808728 T3 ES2808728 T3 ES 2808728T3
Authority
ES
Spain
Prior art keywords
antibody
cancer
tumor
solid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15751324T
Other languages
English (en)
Spanish (es)
Inventor
Satoru Ito
Shoji Yokochi
Kouji Matsushima
Satoshi Ueha
Yoshiro Ishiwata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDAC THERANOSTICS Inc
University of Tokyo NUC
Original Assignee
IDAC THERANOSTICS Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IDAC THERANOSTICS Inc, University of Tokyo NUC filed Critical IDAC THERANOSTICS Inc
Application granted granted Critical
Publication of ES2808728T3 publication Critical patent/ES2808728T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES15751324T 2014-02-21 2015-02-09 Agente terapéutico para cáncer sólido Active ES2808728T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2014032241 2014-02-21
JP2014120300 2014-06-11
JP2014178953 2014-09-03
PCT/JP2015/053569 WO2015125652A1 (ja) 2014-02-21 2015-02-09 固形がんの治療剤

Publications (1)

Publication Number Publication Date
ES2808728T3 true ES2808728T3 (es) 2021-03-01

Family

ID=53878157

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15751324T Active ES2808728T3 (es) 2014-02-21 2015-02-09 Agente terapéutico para cáncer sólido

Country Status (5)

Country Link
US (2) US20170165364A1 (https=)
EP (3) EP3338801A1 (https=)
JP (3) JP6029160B2 (https=)
ES (1) ES2808728T3 (https=)
WO (1) WO2015125652A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359150A4 (en) * 2015-10-05 2019-11-06 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
WO2017217517A1 (ja) * 2016-06-17 2017-12-21 国立大学法人大阪大学 腫瘍内静脈形成促進剤
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
CA3244313A1 (en) 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
JP7302793B2 (ja) * 2018-03-08 2023-07-04 国立大学法人 東京大学 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法
GB201811291D0 (en) * 2018-07-10 2018-08-29 Univ Dublin City A method of predicting response to treatment in cancer patients
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
US20220332825A1 (en) * 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
KR20240004519A (ko) * 2021-04-28 2024-01-11 아센타위츠 파마슈티컬즈 리미티드 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1333850B1 (en) * 2000-10-20 2008-08-20 Genetics Institute, Inc. Use of il-13 inhibitors for the treatment of tumors
PL1897548T5 (pl) * 2003-02-28 2025-03-17 The Johns Hopkins University Regulacja komórek T
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
EP2265643B1 (en) * 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
CN102271711B (zh) * 2008-12-12 2014-06-18 国立大学法人东京大学 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂
PT2374883T (pt) * 2008-12-26 2016-10-20 Kyowa Hakko Kirin Co Ltd Anticorpo anti-cd4
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
US9676854B2 (en) * 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20160108122A1 (en) * 2013-05-23 2016-04-21 Idac Theranostics, Inc. Therapeutic or prophylactic agent for immunodeficiency virus infection
WO2015120198A1 (en) * 2014-02-05 2015-08-13 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
ES2818800T3 (es) * 2014-06-11 2021-04-14 Idac Theranostics Inc Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario

Also Published As

Publication number Publication date
WO2015125652A1 (ja) 2015-08-27
EP3132802B1 (en) 2020-06-17
JP6578604B2 (ja) 2019-09-25
JP7041439B2 (ja) 2022-03-24
US20190125867A1 (en) 2019-05-02
EP3132802A4 (en) 2018-04-18
EP3338800A1 (en) 2018-06-27
JPWO2015125652A1 (ja) 2017-03-30
US20170165364A1 (en) 2017-06-15
JP6029160B2 (ja) 2016-11-24
JP2019070056A (ja) 2019-05-09
EP3132802A1 (en) 2017-02-22
JP2017014254A (ja) 2017-01-19
EP3338801A1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
ES2808728T3 (es) Agente terapéutico para cáncer sólido
JP7726967B2 (ja) 多重特異性結合タンパク質及びその改善
US20230042324A1 (en) Anti-gitr antibodies and uses thereof
ES2818800T3 (es) Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario
BR112020016859A2 (pt) Variantes de il-15 e usos da mesma
TW201722985A (zh) Cd80胞外域多肽及其用於癌症治療
CN105828834A (zh) 检查点抑制剂和治疗剂的组合以治疗癌症
WO2018047917A1 (ja) Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
CN113316449A (zh) 胍那苄作为免疫疗法的佐剂
ES2744936T3 (es) Método para evaluar el efecto terapéutico de un agente antineoplásico que tiene un anticuerpo anti-CD4 como principio activo
CN117603360A (zh) 用于治疗癌症的多特异性抗体
EP4681780A1 (en) Immunocytokine for cancer treatment
Mao et al. Ofek Mussafi1, 2, Jie Mei3, Wenjun Mao1 and Yuan Wan2
EA046081B1 (ru) Мультиспецифические связывающие белки и их усовершенствования
NZ788539A (en) Anti-gitr antibodies and uses thereof
HK40005871B (en) Anti-gitr antibodies and uses thereof
HK40005871A (en) Anti-gitr antibodies and uses thereof
EA039583B1 (ru) Антитела против gitr и их применения